Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a smartphone app help people with obesity lose weight?

NCT ID NCT07183228

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study tests a smartphone app called Eatit that provides a structured lifestyle program with support from a dietitian via video calls and messages. About 93 adults with obesity (BMI 30 or higher) will use the app for six months. Researchers will track changes in weight, waist size, eating habits, and self-rated health to see if the program helps people lose weight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital lifestyle intervention (Eatit app with dietitian support)
What this could lead to
If successful, this could provide an accessible, app-based weight loss program for people with obesity, potentially improving health without in-person visits.
What could go wrong
This is a small pilot study with no control group, so results may not prove the app works better than other methods. Weight loss depends on self-reporting, which can be inaccurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 93 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Body mass index (BMI) ≥ 30 * BMI 27-30 in combination with at least one of the following: 1. Has received a diagnosis of obesity from another healthcare provider. 2. Has a comorbidity (according to the defined diagnosis list under the heading Comorbidities below). 3. Has central obesity, defined as waist circumference \> 80 cm for women or \> 94 cm for men. 4. Kostindex score of 4 or lower - eligible for treatment due to increased risk of rapid future weight gain. Dietitian-led intervention may significantly impact weight development in this group. * Ability to read and understand Swedish * Does not currently use, and does not plan to initiate the use of, appetite-suppressing medication * Not pregnant * Patients with BMI \> 40, As long as there is no contraindication for treatment, treatment is offered. A dietitian may deny the patient the Eatit program if the dietitian assesses that the need for care is too great, and that Eatit's treatment cannot meet the patient's needs. Comorbidities: * Cardiovascular disease This is a large group of diagnoses, e.g. previous myocardial infarction or stroke, angina pectoris, heart failure, etc. * Hypertension * Elevated blood pressure, above 130/85 mmHg or ongoing treatment for previously diagnosed hypertension * Hyperlipidemia * Triglyceride levels ≥ 1.7 mmol/L or on treatment for elevated triglycerides, or LDL \> 3.0 mmol/L at low risk, or on treatment for high cholesterol, or reduced HDL-C \<40 mg/dL for men, \<50 mg/dL for women, or on treatment for HDL-C * Obstructive sleep apnea * Type 1 diabetes * Type 2 diabetes * Prediabetes (fasting glucose ≥ 6.1 or HbA1c \> 42 without a diabetes diagnosis) * Fatty liver * Polycystic ovary syndrome, PCOS * Osteoarthritis in the lower body (e.g. hip, knee, or foot) Exclusion Criteria: * BMI: Patients with BMI \< 27 are excluded from treatment. * Medical conditions: Patients with conditions where weight loss or weight gain may worsen the disease are excluded. For example: cancer or chronic obstructive pulmonary disease, COPD. * Multimorbidity: Individuals with extensive comorbidities may have complex healthcare needs requiring more comprehensive medical support than Eatit can provide. * Untreated depression may hinder participation in the program and should be managed with medical or psychological support. * Untreated or ongoing eating disorder (bulimia nervosa, binge eating disorder, anorexia, atypical anorexia, ARFID) should be treated in a specialized eating disorder unit. * Severe psychiatric illness (such as psychosis or schizophrenia) without ongoing support. * Ongoing substance abuse (alcohol, narcotics, or medication) is a contraindication for participation and requires specialized addiction care. * Suicidal behavior or self-harm in the past six months. Acute mental illness requires immediate and specialized interventions. * Requires individual assessment. Certain conditions require individual evaluation as they may negatively affect treatment outcomes. This means that the treating dietitians should ask follow-up questions to ensure that participation in the program is feasible. * Symptoms of binge eating not meeting criteria for binge eating disorder: Ensure that the person is willing to work with the program, not skip meals, and will inform you if the binge eating worsens. * Depression under psychiatric care: Ask follow-up questions about what support the person is receiving and his or her current mental state. * Bipolar disorder: Ask follow-up questions about what support the person is receiving and his or her current mental state. * Exhaustion syndrome/stress: Ask follow-up questions to determine whether treatment is feasible at this time or if the patient needs to manage the stress in other ways first. * Neuropsychiatric disorders: To benefit from the program, sufficient concentration ability and capacity for structure/planning in daily life are required. In case of a neuropsychiatric diagnosis, follow-up questions should be asked about whether the person believes that he or she can manage texts and tasks that take approximately 2-3 hours per week. * High degree of psychiatric comorbidity has in some studies been shown to be a complicating factor, and this should also be considered at the start of treatment. Ask follow-up questions about what support the person is receiving and his or her current mental state. * Severe sleep problems: Sleep deprivation may lead to increased appetite and reduced cognitive capacity, making it difficult to engage with treatment. Ask follow-up questions about possible undiagnosed sleep apnea or potential need for other care to address the sleep problems.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese patients (bmi ≥ 30 KG/m²) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eatit AB

    RECRUITING

    Stockholm, Stockholm County, 120 30, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.